Abcellera Biologics Inc (ABCL NASDAQ) stock market data APIs
$5.7841
0.34(5.9%)
as of October 16, 2025
Try our APIs with
free plan!
Abcellera Biologics Inc Financial Data Overview
Price chart is built with
Anychart
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Prev. Close
5.7841
Open
6.1228
High
6.2247
Low
5.7723
52 wk Range
1.8906-6.515
Market Cap
1 745 M
Shares Outstanding
299 M
Revenue
32 876 K
EPS
-0.12
Beta
0.69
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Abcellera Biologics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Abcellera Biologics Inc data using free add-ons & libraries
Get Abcellera Biologics Inc Fundamental Data
Abcellera Biologics Inc Fundamental data includes:
- Net Revenue: 32 876 K
- EBITDA: -218 379 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: -0.14
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Abcellera Biologics Inc News
New
Nuvation Bio Inc. (NUVB): A Bull Case Theory
We came across a bullish thesis on Nuvation Bio Inc. on wallstreetbets subreddit by asagi_lumina. In this article, we will summarize the bulls’ thesis on NUVB. Nuvation Bio Inc.'s share was trading ...
Is ABCELLERA BIOLG (ABCL) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has AbCellera Biologics Inc. (ABCL) been one of those stocks thi...
New CMO Appointment Strengthens AbCellera Biologics Inc. (ABCL)’s Push Into Immunology and Beyond
In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. AbCellera Biologics Inc. stands amongst them. AbCellera Biologics Inc. (NASDAQ:ABCL) is entering a new ph...
AbCellera Biologics Inc. (ABCL) Appoints Chief Medical Officer
AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the best healthcare penny stocks to buy now. On September 10, the company confirmed the appointment of Sarah Noonberg, M.D., Ph.D., as its Chief Medica...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
